Amryt presents new analyses from the ease phase 3 trial in epidermolysis bullosa at spd 2022

Amryt presents new analys e s from the ease phase 3 trial in epidermolysis bullosa at spd 2022

AMYT Ratings Summary

AMYT Quant Ranking